Great close, plenty of appetite for these shares still, giving sure but steady gains The dispersion work must be nearly complete & expecting plenty more newsflow to come over the next couple of months.
Exactly all abut the upside. IMO It wouldn't take a great deal more work to become at 20/30 Mill mcap company and that is prior to any commercial deals.
"The global viral vector manufacturing market was valued at $273 million in 2017 and is expected to grow to $816 million by 2023 . Sales of transduction reagents were estimated to be $68m in 2017 and growing to $123m by 2024.
Little drift after a sharp move up.. As Leister said, much more to come here.
5.4m cap is peanuts compared to what we could be looking at in the future. Next stage are the in vitro studies and these have been shown to work every time when previously carried out by N4.
Sales for YE June 19 was £151 mill and for the 6 months to Dec 19 £81mill with adjusted EBITDA of 12Mill. The YOY figures have been improving and Debt reducing under good management. Net assets at end of last full year were £21 mill. Credit facility has been temporarily increased with NatWest.
Highly cash generative. Sitting at 12mill mcap....!!
Obvs' the next month or two there will may be no trading but this is a thriving and improving business and the customers will be back as soon as they can be.
Castlefield Fund has now fully out and SP been improving ever since. I think this is priced for failure. Of course there are risks but baring a doomsday scenario for british bars i think the SP will continue to see a very nice recovery given a bit of time.